These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12932672)

  • 1. The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
    D'Incalci M; Colombo T; Ubezio P; Nicoletti I; Giavazzi R; Erba E; Ferrarese L; Meco D; Riccardi R; Sessa C; Cavallini E; Jimeno J; Faircloth GT
    Eur J Cancer; 2003 Sep; 39(13):1920-6. PubMed ID: 12932672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
    Meco D; Colombo T; Ubezio P; Zucchetti M; Zaffaroni M; Riccardi A; Faircloth G; Jose J; D'Incalci M; Riccardi R
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):131-8. PubMed ID: 12783202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
    Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
    Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft.
    Riccardi A; Meco D; Ubezio P; Mazzarella G; Marabese M; Faircloth GT; Jimeno J; D'Incalci M; Riccardi R
    Anticancer Drugs; 2005 Sep; 16(8):811-5. PubMed ID: 16096428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
    Valoti G; Nicoletti MI; Pellegrino A; Jimeno J; Hendriks H; D'Incalci M; Faircloth G; Giavazzi R
    Clin Cancer Res; 1998 Aug; 4(8):1977-83. PubMed ID: 9717828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
    Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
    Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
    Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
    J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
    Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
    BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
    Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
    Eur J Cancer; 2009 Aug; 45(12):2116-22. PubMed ID: 19419856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin combined with the new cisplatin-procaine complex DPR: in vitro and in vivo studies.
    Viale M; Vannozzi MO; Merlo F; Cafaggi S; Parodi B; Esposito M
    Eur J Cancer; 1996 Dec; 32A(13):2327-33. PubMed ID: 9038617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line.
    Formelli F; Cleris L
    Eur J Cancer; 2000 Dec; 36(18):2411-9. PubMed ID: 11094318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice.
    Shalinsky DR; Bischoff ED; Gregory ML; Lamph WW; Heyman RA; Hayes JS; Thomazy V; Davies PJ
    Clin Cancer Res; 1996 Mar; 2(3):511-20. PubMed ID: 9816198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
    Levasseur LM; Greco WR; Rustum YM; Slocum HK
    Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.